Gillian McGovern, Editor

CDK4/6 inhibitor therapies must by tailored by comorbidities, interactions, cost, and coordinated labs with pharmacist expertise to support high-risk patients.

The FDA approval of the Wegovy pill offers a new, effective GLP-1 option for weight management, with pharmacists playing a key role in patient counseling and adherence support.

The expanded indication is supported by findings from the phase 3 TRANSCEND clinical trial.

RUNX1 in microglia helps predict opioid pain relief, higher morphine needs, and withdrawal severity—pointing to genetic screening and safer, personalized pain management.

Although the rates of gabapentin use without a prescription were nearly double those of prescribed use, the trends are decreasing over time.

MS requires interdisciplinary collaboration, including pharmacists who can support patients throughout disease management.

The experts express their concerns that current ACIP decisions and guidelines are not backed by "pure science."

To combat vaccine-related misinformation and disinformation, the speakers emphasize the importance of integrated education, community-led advocacy, and proactive outreach.

The second part of this video series highlights thoughts from 4 panelists on shared clinical decision-making and how harmful misinformation is in the health care space.

Phase 4 data show suzetrigine controls post–plastic surgery pain, keeping nearly 91% of patients opioid free with good pain ratings and tolerability.

A group of experts provide insights and answer questions to some of the more pressing topics around changes in vaccine schedules and policies.

Launching sustainable, effective CGT programs requires a road map for strategy, operations, access, finance, quality, and pharmacy.

Milsaperidone is indicated for acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia in adults.

VOYAGE trial data show dupilumab improves pediatric asthma control and lowers exacerbations versus placebo, with higher remission and lung function gains earlier.

Phase 2 trial data support the safety and efficacy of remibrutinib in adults with peanut allergy.

Data show the peanut allergy sublingual immunotherapy (SLIT) tablet is well-tolerated across ages, offering promising sublingual immunotherapy desensitization with manageable adverse effects.

AAAAI 2026 highlights STMC-103H live biotherapeutic, showing reduced atopic disease risk in at-risk infants—potentially an early microbiome intervention for atopic dermatitis and food allergy.

Remibrutinib, an oral Bruton tyrosine kinase inhibitor for chronic spontaneous urticaria (CSU), delivers itch and hive relief within 12 hours and sustains improvements through week 1.

Data presented at AAAAI 2026 show tapinarof cream improves sleep for children as young as 2 years with atopic dermatitis, easing nighttime disruption.

The approval is supported by findings from the phase 1 Beamion LUNG-1 clinical trial.

The approval for the oral, fixed-duration chronic lymphocytic leukemia (CLL) regimen was based on results from the phase 3 AMPLIFY trial.

Study authors suggest that VA and health care professionals should educate patients on the medical evidence, gaps, policies, and laws related to cannabis.

With this action, dupilumab has become the first and only FDA-approved treatment for allergic fungal rhinosinusitis.

The authors urge air quality interventions to promote and support dementia prevention strategies.

A pressure vibration device can cut propofol injection pain in patients undergoing surgeries, matching low-dose ketamine without extra adverse events.

The biosimilar is a cost-effective treatment for patients with conditions caused by cancer treatment.

Universal aspirin at the first prenatal visit lowers severe preeclampsia rates in high-risk pregnancies, delaying onset without raising hemorrhage or placental abruption risk.

ALZ-801, an oral anti–amyloid oligomer therapy, shows cognitive, functional, and brain-volume benefits in the mild cognitive impairment (MCI) stage of Alzheimer disease, with supportive biomarkers and no edema risk.

Both formulations were also well-tolerated and withdrawal was rare.

The label change removes boxed warnings of cardiovascular disease, breast cancer, and probable dementia from certain hormone replacement therapy products.